Milestone Pharmaceuticals Inc. (MIST) Expands Phase 3 AFib-RVR Trial to Canada

Milestone Pharmaceuticals enrolled the first Canadian participant in its ReVeRA-301 Phase 3 trial of etripamil nasal spray for AFib-RVR, targeting ~150 treated events and using the FDA-approved 70 mg repeat-dose regimen used in PSVT.Material DetailsContext by AI AnalystThis is a mid-cycle execution…